Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bio-Thera Cleared for US Trial of FRα ADC for Solid Tumor Cancers

publication date: Mar 26, 2024

Guangzhou Bio-Thera was cleared to start a US Phase II trial for BAT8006, an ADC targeting Folate Receptor α (FRα). The study will enroll patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. BAT8006 was developed using Bio-Thera's proprietary anti-FRα antibody and proprietary ADC linker-payload combination inhibitor. In preclinical studies, the candidate showed potential for good stability and safety along with strong anti-tumor activity. The company said BAT8006 showed a strong bystander effect in a Phase I trial. Bio-Thera is developing a portfolio of 24 novel and biosimilar candidates. More details....

Stock Symbol: (SHA: 688177)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital